Navigation Links
Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
Date:4/19/2013

BETHESDA, Md., April 19, 2013 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco™ in combination with another potential CF therapy, VX-661. The results showed a significant improvement in lung function in people with two copies of the most common CF mutation, Delta F508, who took the combination treatment, compared with those who received a placebo. About 50 percent of people with CF in the United States have two copies of the Delta F508 mutation.

Both Kalydeco and VX-661 are designed to treat the underlying cause of CF, a faulty gene and its protein product, known as CFTR.

"This announcement is more terrific news for the CF community," said Robert J. Beall , Ph.D., president and CEO of the Cystic Fibrosis Foundation. "While these results are still very early, they show that another potential therapy from our ongoing collaboration with Vertex can be combined with Kalydeco to achieve promising improvements in health. The data further validate our strategy of using small molecule compounds to address the basic genetic defect in cystic fibrosis."

The CF Foundation played a key role in the development of Kalydeco and VX-661, as well as other experimental compounds such as VX-809, providing significant scientific, clinical and financial support. Vertex is studying Kalydeco with VX-809 in Phase 3 trials that will enroll about 1,000 people at approximately 200 clinical trial sites in North America, Europe and Australia. "The CF Foundation is deeply grateful to the people with CF, families and medical professionals who have played a role in these studies, and to the Vertex scientists who remain dedicated to advancing CF drug development," said Beall.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Alarm Concepts Files Information Statement and Provides Update on Corporate Activity
2. Joint Statement On The Presidents Budget From The American Society Of Clinical Oncology, Community Oncology Alliance, ION Solutions and The US Oncology Network
3. Receptos Files Registration Statement for Proposed Initial Public Offering
4. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
5. National Cancer Organizations Issue Joint Statement On Devastating Impact Of Sequestration
6. AUGS Issues Statement Opposing The Restriction Of Surgical Options For Pelvic Floor Disorders
7. Bausch + Lomb Files Registration Statement For Proposed Initial Public Offering
8. CHPA Statement on Statewide South Carolina Consumer Poll
9. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
10. Chimerix Files Registration Statement for Proposed Initial Public Offering
11. CHPA Statement on PSE Economic Study By AEI Fellow Alex Brill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017 The Institute for In ... is the recipient of a VITROCELL® inhalation exposure system ... Science Consortium. The device, which is designed to replace ... human lung cells to airborne test materials in an ... the VITROCELL® system for testing combustible tobacco products, as ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first ... the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions ... activity levels decline over time. The study, presented today at the American ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
(Date:7/20/2017)... ... 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the 2017 ... , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every ...
(Date:7/20/2017)... ... 2017 , ... The Dermatology Clinic announced today the addition of Dr. Scott ... from LSU, graduating summa cum laude. He attended Emory University School of Medicine in ... Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship ...
Breaking Medicine News(10 mins):